<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle23
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle24
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle25
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle26
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle27
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle28
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.EmailStyle29
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle30
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.EmailStyle31
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle32
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:453863304;
mso-list-template-ids:799976568;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:527527648;
mso-list-template-ids:-1861180308;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:1053164493;
mso-list-template-ids:-5193218;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:1293288997;
mso-list-template-ids:-1273603704;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4
{mso-list-id:1750343237;
mso-list-template-ids:-387166280;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:2124494785;
mso-list-template-ids:1340516732;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.td.com_corporate-2Dresponsibility_ready-2Dcommitment_ready-2Dchallenge.jsp&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=OD5IFS_h4qfOip1lss85HKid4aP6cPQwhaNSMZtxaKY&e=" target="_blank">TD Ameritrade Ready Challenge: Better Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The TD Ready Challenge is an annual North American initiative that has up to ten $1 million (CAD) grants available to catalyze innovative solutions for a changing world. Recipients will
be organizations that have impactful and measurable solutions that will help open doors for a more inclusive and sustainable tomorrow.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">The 2019 Problem Statement: Better Health</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Research has shown a clear link between financial health and physical health. People with strong financial health experience less stress, access regular preventative healthcare, make healthier
choices and take prescribed medication. People with strong physical health are able to work longer and are better equipped to deal with financial issues. Today, advances in healthcare are helping many people lead healthier lives.<sup>1</sup> One reason is
an increase in the ability to screen for and detect diseases at an earlier stage. That way interventions can occur sooner, making them less costly and more effective. Unfortunately, research has also shown that access to quality healthcare, including awareness
and advancements related to early screening and intervention, may not be experienced equally across all communities and may differ based on a number of factors. These factors include race, ethnicity, socioeconomic status and geographic location. Specifically,
we are seeking to fund programs, grounded in clinical solutions, that <b>focus on preventative efforts</b>, such as screening, early detection and intervention innovations, aimed at reducing the onset, development and severity of chronic disease<sup>2</sup>
and other illnesses and satisfy any one or both of the following criteria:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Aim to improve on existing healthcare practices and services to help reach underserved and remote populations (Canada) and/or low to moderate income populations
(U.S)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Utilize technologies to reach underserved and remote populations (Canada) and/or low to moderate income populations (U.S)<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 23, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: August 9, 2019.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__curingkidscancer.org_pdfs_ckc-2Drfp-2D2019.pdf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=aC269nLL0dZjujOb9CbXFP4rTuWXcWaKV4yd8AG7R9o&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Curing Kids Cancer: Innovative Research Awards</span></a><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of these grants is to overcome barriers to clinical application of new treatment approaches for childhood cancer. A priority is to fund projects that have already shown great
promise, but that have a specific funding need to move forward. The three main focus areas for this RFP are<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Cancer immunotherapy / targeted therapy<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">High-grade brain tumors<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Therapeutic targeting through genomics / epigenetics<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Application of novel technologies in these areas are welcome. Applications to fund correlative studies associated with clinical trials in the focus areas will be considered. Funding for
the associated clinical trial must have already been secured and applications must include a description of the developmental pathway for the therapeutic approach.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Two types of one-year grants will be awarded:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l4 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Collaborative: One multi-institutional collaborative grant award of $300,000<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo9"><span style="font-size:12.0pt;font-family:Palatino">Individual: Two individual grant awards of $150,000 each<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">10% IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 9, 2019.
<span style="color:red">Med-RA deadline to receive draft documents: August 23, 2019.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ncrg.org_sites_default_files_uploads_seed-5Fgrants-5Fannouncement-5F2019.pdf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=9KaNlSIUvN3DKqRICODLm-s0GOGQwv9npdO5RugOc48&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">National Center for Responsible Gaming: Seed Grants for Research on Gambling
Disorder</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">In support of its mission, the National Center for Responsible Gaming is inviting applications for the 2019 Seed Grant for Research on Gambling Disorder. Through the program,
grants of up to $30,000 (plus 15 percent for facilities and administration costs) will be awarded to proposals with high scientific merit that explore the etiology, prevention, and treatment of gambling disorder. The program supports a variety of research
activities, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; the development of research methodologies; and the development of new research technology. The 2019 call for proposals is intended
to support research with direct implications for gambling policy, although proposals based on topics other than policy are welcome.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due August 1, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: July 18, 2019.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D294.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=6f57ogGbXaN_euEZwkYkFQW74Ju7Q0DFvrPn4rkKGp8&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01
Clinical Trial Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts
in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition,
kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available at
</span><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.niddk.nih.gov_research-2Dfunding_research-2Dprograms_Pages_default.aspx&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=S9u-_NqlZMOG7j7VJ2Mzh-U_Hfp91DxmBJEq_gOZe7Q&e="><span style="font-size:12.0pt;font-family:Palatino">www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx</span></a><span style="font-size:12.0pt;font-family:Palatino">
and applicants are strongly encouraged to discuss research priorities with the Scientific Contact. The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called
“therapeutic leads”) such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic
and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative
new targets, or identifying new therapeutic uses for existing compounds. At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity around a therapeutic such that it can advance
further through other funding mechanisms, such as the small business program (</span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__sbir.nih.gov_niddk_index&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=o2BfY54vzWWMEj_lzVM3h5cEkE8OM0os95c6h69QJ0M&e="><span style="font-size:12.0pt;font-family:Palatino">https://sbir.nih.gov/niddk/index</span></a><span style="font-size:12.0pt;font-family:Palatino">).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 12, 2019; July 14, 2020; November 12, 2020; July 14, 2021; and November 12, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for November 2019 deadline: October 29.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D295.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=jvY6potXNkf3HE-i-k_JX_irp-zwz9MtO075tbQhAos&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Research to Understand and Inform Interventions that Promote the Research Careers of Individuals
in the Biomedical Sciences (R01 – Clinical Trial Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) encourages applications that propose research designed to test training, mentoring, and networking interventions intended to enhance
research-oriented individuals’ interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the design and implementation of interventions in
a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires January 8, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for October 2019 deadline: September 23.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D298.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=utPmXsmXMRHn7JsbMW0lrkn-id-HyzJa4XMJk5emDIU&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer’s
disease (AD) or Alzheimer’s disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination
interventions are allowed, provided the focus and innovative component is neurostimulation.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Applications that seek to develop devices, tools, or invasive techniques are outside the scope of this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires September 8, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for October 2019 deadline: September 23.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D297.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=8xlaC0Y3cCTtBBeFnu_afgexU9yCNeeSR72iqBrr5j4&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary
areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or
more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation.
In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal
Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires January 8, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for October 2019 deadline: September 23.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">For postdocs:</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black">
</span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D296.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=POJV9Qm5KtyQWUe-bhoRETyyBp61ih95EbEYcI-5fLc&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The NIAID New Innovator Awards supports post-doctoral investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce
a major impact on broad, important problems in biomedical research of priority to NIAID. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due October 10, 2019; October 14, 2020; and October 13, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for October 2019 deadline: September 26.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><b><span style="font-size:12.0pt;font-family:Palatino;color:red">CoM’s
unofficial funding opportunities blog</span></b></a><b><span style="font-size:12.0pt;font-family:Palatino;color:red">.</span></b><span style="font-size:12.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"> </span><span style="font-size:12.0pt"><o:p></o:p></span></p>
</div>
</body>
</html>